/content/mofsl-website-adobe/fragments/open-demat-popup
style
hide-in-desktop

US Stock Details

Get in-depth insights on US stocks, including fundamentals, financials, shareholding, peer comparison, and performance. Track key metrics, price trends, and market sentiment for informed decisions. Stay ahead with expert analysis and data-driven strategies at Motilal Oswal.

style
pb-0

Pasithea Therapeutics Corp

us-stock
To Invest in {{usstockname}}
/content/mofsl-website-adobe/demat-form-fields
style
sticky-block,pt-0
us-stock
style
pt-0
$1.17 -0.0168(-1.68%) KTTA at 04 Dec 2025 04:36 PM Biotechnology
Lowest Today 1.145
Highest Today 1.33
Today’s Open 1.2
Prev. Close 1.19
52 Week High 3.85
52 Week Low 0.28
Day’s Range: Low 1.145 High 1.33
52-Week Range: Low 0.28 High 3.85
1 day return -
1 Week return -19.86
1 month return +63.61
3 month return +48.79
6 month return +26.55
1 year return -58.65
3 year return -93.73
5 year return -
10 year return -

Institutional Holdings

AdvisorShares Psychedelics ETF 3.08

AdvisorShares Investments, LLC 2.60

Citadel Advisors Llc 0.63

UBS Group AG 0.57

Fidelity Extended Market Index 0.20

LPL Financial Corp 0.13

Vanguard Institutional Extnd Mkt Idx Tr 0.12

Hurley Capital, LLC 0.05

Spartan Total Market Index Pool G 0.03

Northern Trust Extended Eq Market Idx 0.02

NT Ext Equity Mkt Idx Fd - L 0.02

Fidelity Series Total Market Index 0.02

Tower Research Capital LLC 0.02

SBI Securities Co Ltd 0.01

NT Ext Eq Mkt Indx Fd DC Lending Tier 5 0.01

NT Ext Eq Mkt Indx Fd DC Lend T3 0.01

Royal Bank of Canada 0.00

JPMorgan Chase & Co 0.00

Bank of America Corp 0.00

Fidelity U.S. Equity Index Ins Trust 0.00

Armistice Capital, LLC 0.00

Citigroup Inc 0.00

Morgan Stanley - Brokerage Accounts 0.00

Market Status

Strong Buy: 1

Buy: 0

Hold: 0

Sell: 0

Strong Sell: 0

Fundamentals

Market Cap 26.65 M

PB Ratio 0.8964

PE Ratio 0.0

Enterprise Value -1.03 M

Total Assets 16.06 M

Volume 1994958

Company Financials

Annual Revenue FY23:486559 0.5M, FY22:486559 0.5M, FY21:15062 0.0M, FY20:null 0.0M

Annual Profit FY23:null 0.0M, FY22:373364 0.4M, FY21:-2213 -0.0M, FY20:null 0.0M

Annual Net worth FY23:-16031187 -16.0M, FY22:-13056481 -13.1M, FY21:-2174029 -2.2M, FY20:null 0.0M

Quarterly Revenue Q3/2025:0 0.0M, Q2/2025:0 0.0M, Q1/2025:0 0.0M, Q3/2024:0 0.0M, Q2/2024:0 0.0M

Quarterly Profit Q3/2025:-181541 -0.2M, Q2/2025:-161745 -0.2M, Q1/2025:-161707 -0.2M, Q3/2024:null 0.0M, Q2/2024:-162256 -0.2M

Quarterly Net worth Q3/2025:-3037420 -3.0M, Q2/2025:-3716157 -3.7M, Q1/2025:-3563238 -3.6M, Q3/2024:-2999834 -3.0M, Q2/2024:-3866249 -3.9M

Fund house & investment objective

Company Information Pasithea Therapeutics Corp., a clinical-stage biotechnology company, focuses on the discovery, research, and development of treatments for central nervous system (CNS) disorders, RASopathies, and cancers. Its lead product candidate is PAS-004, a next-generation macrocyclic mitogen-activated protein kinase, or MEK inhibitor to treat a range of RASopathies, including neurofibromatosis type 1 (NF1); MAPK pathway-driven tumors, such as BRAFv600 and BRAF fusion tumors; and ETS2 driven diseases, including inflammatory bowel disease (IBD), primary sclerosing cholangitis, and ankylosing spondylitis. The company's lead development candidate is PAS-003, to treat amyotrophic lateral sclerosis. It also intends to develop PAS-001, to treat schizophrenia. Pasithea Therapeutics Corp. was incorporated in 2020 and is headquartered in Miami Beach, Florida.

Organisation Biotechnology

Employees 4

Industry Biotechnology

CEO Dr. Tiago Reis Marques M.D., Ph.D.

Trading and brokerage services provided by

Technology Services provided by Motilal Oswal Financial Services:

Disclaimer: These services are not for exchange traded products. The securities quoted are exemplary and not recommendatory. Please be informed that US Stocks are not exchange traded funds in India and Motilal Oswal Financial Services acts in the capacity of facilitator of this product. All disputes with respect to the transaction facilitation services, would not have access to Indian Exchange investor redressal forum or Arbitration mechanism in India. T&C apply*

Take your next step

Talk to our investment advisor for stock recommendations
Left
Get expert assistance for portfolio management
Right
style
align-center,button-arrow